High Quality | Rapid | Scalable | Competitive
We offer services in protein expression production. We pride ourselves on being experts in the expression and the production of proteins, including antibodies and allergens, enzymes and vaccines. Our protein production services use our plant-based transient expression technology and as a result, delivers rapid, scalable production of quality products that are competitive to produce.
It is our goal at Leaf Expression Systems to help improve lives. We aim to do this by accelerating clients’ research and lowering costs in the development and manufacture of therapeutic drugs, vaccines, and diagnostics.
Unlike more conventional protein expression systems, we believe our technology can deliver drugs more quickly and more cost-effectively, thereby reducing the time from clinic to market. Not only does this help to reduce the time it takes to get new drugs to patients and at a cheaper cost but can cut the time to market by at least 7 months.
Plant-based transient expression systems have significant technical advantages and as a result, enable us to deliver the rapid and scalable production of high-quality products.
Originally developed at the world-renowned John Innes Centre in Norwich, the Hypertrans® system is the core technology to our business. The system allows for the simultaneous production of multiple gene products in a controlled and coordinated manner within the tissues of plants.
We produce proteins, including antibodies and allergens, enzymes and vaccines. All of our products are of the highest quality and made without using animal derivatives, which importantly eliminates the risk of any animal-derived infectious material being processed within the new drugs.
Our products are produced at our state-of-the-art facility by Agrobacterium-mediated transient expression in Nicotiana benthamiana and are all designed and engineered to appropriate containment and safety standards.
We offer protein expression production services. This includes custom design, expression, and purification of client proteins for a range of applications. Applications such as therapeutic drugs, vaccine development, diagnostics, biophysical analysis, and structural biology for instance.
Our key technology is the Hypertrans® system using Agrobacterium-mediated transient eukaryotic expression within Nicotiana benthamiana. The Hypertrans® system promotes extremely high-level and rapid production of proteins without viral replication and is efficient, safe and simple to use.
We are a Contract Development and Manufacturing Organisation (CDMO). Plant-based expression and the production of proteins, vaccines and complex natural products for research and commercial applications is what we specialise in.
The company is based in a purpose-built, state-of-the-art facility on the Norwich Research Park,UK. The facility has environmentally controlled growing rooms supported by plant potting areas, a plant inoculation area, microbiology/molecular biology labs, protein purification and natural product processing facilities.
The quality of our products and services are without doubt key to our success. This however is only possible by having a highly specialised team in place. Our team is the bricks and mortar of our business and is what drives us forward.
Our scientific team are all experts in plant-based expression, with backgrounds in pharma, academia, biotech, commercial science and international life science industries.
Companies work with us to develop and scale the production of their products and intermediates. We also work with academic scientists, including grant funded projects to translate their science into scalable processes or to develop new enabling technologies.
Leaf Expression Systems Appoints Dr. Leanne Williams as its Business Development ManagerJuly 21, 2020
Leaf Expression Systems Aids Research into the Novel Coronavirus (SARS-CoV-2, 2019-nCoV) with the Development of Recombinant SARS-CoV-2 N-ProteinJune 17, 2020
Plant-based expression systems have a range of technical advantages. These include; insertion gene size, yield, propagation, protein assembly and folding accuracy, product quality and homogeneity, distribution and storage temperature, together with scale-up, speed and flexibility this leads to significant reductions in manufacturing costs of goods and above all, costs to patients.
The Hypertrans® system allows for the rapid simultaneous production of multiple gene products in a controlled and coordinated manner within the tissues of plants. Using gene synthesis and modular vectors, new products such as vaccines, antibodies or enzymes can be rapidly produced on a large scale therefore making it well suited to be able to rapidly respond to emergencies like pandemics.